{"id":380655,"date":"2020-11-13T07:03:26","date_gmt":"2020-11-13T12:03:26","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=380655"},"modified":"2020-11-13T07:03:26","modified_gmt":"2020-11-13T12:03:26","slug":"bioxcel-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/","title":{"rendered":"BioXcel Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">NEW HAVEN, Conn., Nov.  13, 2020  (GLOBE NEWSWIRE) &#8212; BioXcel Therapeutics, Inc. (\u201cBTI\u201d or the \u201cCompany\u201d) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference.<\/p>\n<p>\n        <strong>Presentation Details:<\/strong><br \/>\n        <br \/>\n        <strong>Event:<\/strong> Jefferies Virtual London Healthcare Conference<br \/><strong>Date:<\/strong> Thursday, November 19, 2020<br \/><strong>Time:<\/strong> 7:20 PM GMT\/2:20 PM ET<\/p>\n<p>A live webcast of the fireside chat will be accessible through the Investors section of the Company&#8217;s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zaqgzpP4hryCG4XyGy_DBnIrfszpk5Wwp_KLTan5SdG9_eAxIQg0T-B3DwsvImyhlz0xi3g3hz4qkmyfk8gE5dufh16sDipa6fc1TbIKhDCMtxCCsdBbe9PJVVlVXTo0\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.bioxceltherapeutics.com<\/a>. Following the conference, the webcast will be archived on the Company\u2019s website for at least 30 days.<\/p>\n<p>\n        <strong>About BioXcel Therapeutics, Inc.<\/strong>\n      <\/p>\n<p>BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. BTI&#8217;s drug re-innovation approach leverages existing approved drugs and\/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI&#8217;s two most advanced clinical development programs are BXCL501, an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the treatment of agitation and opioid withdrawal symptoms, and BXCL701, an investigational, orally administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment na\u00efve to checkpoint inhibitors. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zaqgzpP4hryCG4XyGy_DBnIrfszpk5Wwp_KLTan5SdEuenk6qVBzybh2G5pSVQfH-mdBmEuX0Ya9w0zIdzgDhyIExPaJMCmf5nbPFZ7gwCyGv85A4O0teVlJkyBIRsOT\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.bioxceltherapeutics.com<\/a>.<\/p>\n<p>Contact Information:<br \/>BioXcel Therapeutics, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zaqgzpP4hryCG4XyGy_DBnIrfszpk5Wwp_KLTan5SdGDToChVS3uWY8xUPG24434ir_9cNjbUmRQp3vuEH0fbbvVdmYOAdu76S1rnaQuk06JdWLE_aHlBMmebAoeLis-\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.bioxceltherapeutics.com<\/a><\/p>\n<p>Investor Relations:<br \/>John Graziano<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ej0-7ckcVgsqV4vaXmmLabbhOMyRecDgx7d60uuf__8OwMYucKpoTCaboDsgIvm-qGBcgQTnqAu13dz1GTj2i9jVcGxuzGD2IIeZijMeMdc=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">jgraziano@troutgroup.com<br \/><\/a>1.646.378.2942<\/p>\n<p>Media:<br \/>Julia Deutsch<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ItK1MAZ9Qx9kWD6m3zRQ4KPdkEqHiwEG1b43Q25fraCsIOwMt41-H1-W4gLgPuD4p_VhcE_Z-iameRrt--38VgZxdu79V924TeOIpaUZG48=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">jdeutsch@troutgroup.com<br \/><\/a>1.646.378.2967<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTQ2MSMzODI1MzUwIzIxOTI5NTc=\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW HAVEN, Conn., Nov. 13, 2020 (GLOBE NEWSWIRE) &#8212; BioXcel Therapeutics, Inc. (\u201cBTI\u201d or the \u201cCompany\u201d) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference. Presentation Details: Event: Jefferies Virtual London Healthcare ConferenceDate: Thursday, November 19, 2020Time: 7:20 PM GMT\/2:20 PM ET A live webcast of the fireside chat will be accessible through the Investors section of the Company&#8217;s website at www.bioxceltherapeutics.com. Following the conference, the webcast will be archived on the Company\u2019s website for at least 30 days. About BioXcel Therapeutics, Inc. BioXcel Therapeutics, Inc. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BioXcel Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-380655","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BioXcel Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioXcel Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW HAVEN, Conn., Nov. 13, 2020 (GLOBE NEWSWIRE) &#8212; BioXcel Therapeutics, Inc. (\u201cBTI\u201d or the \u201cCompany\u201d) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference. Presentation Details: Event: Jefferies Virtual London Healthcare ConferenceDate: Thursday, November 19, 2020Time: 7:20 PM GMT\/2:20 PM ET A live webcast of the fireside chat will be accessible through the Investors section of the Company&#8217;s website at www.bioxceltherapeutics.com. Following the conference, the webcast will be archived on the Company\u2019s website for at least 30 days. About BioXcel Therapeutics, Inc. BioXcel Therapeutics, Inc. &hellip; Continue reading &quot;BioXcel Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-13T12:03:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTQ2MSMzODI1MzUwIzIxOTI5NTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BioXcel Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference\",\"datePublished\":\"2020-11-13T12:03:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/\"},\"wordCount\":272,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTQ2MSMzODI1MzUwIzIxOTI5NTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/\",\"name\":\"BioXcel Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTQ2MSMzODI1MzUwIzIxOTI5NTc=\",\"datePublished\":\"2020-11-13T12:03:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTQ2MSMzODI1MzUwIzIxOTI5NTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTQ2MSMzODI1MzUwIzIxOTI5NTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioxcel-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioXcel Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioXcel Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"BioXcel Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference - Market Newsdesk","og_description":"NEW HAVEN, Conn., Nov. 13, 2020 (GLOBE NEWSWIRE) &#8212; BioXcel Therapeutics, Inc. (\u201cBTI\u201d or the \u201cCompany\u201d) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference. Presentation Details: Event: Jefferies Virtual London Healthcare ConferenceDate: Thursday, November 19, 2020Time: 7:20 PM GMT\/2:20 PM ET A live webcast of the fireside chat will be accessible through the Investors section of the Company&#8217;s website at www.bioxceltherapeutics.com. Following the conference, the webcast will be archived on the Company\u2019s website for at least 30 days. About BioXcel Therapeutics, Inc. BioXcel Therapeutics, Inc. &hellip; Continue reading \"BioXcel Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-13T12:03:26+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTQ2MSMzODI1MzUwIzIxOTI5NTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BioXcel Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference","datePublished":"2020-11-13T12:03:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/"},"wordCount":272,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTQ2MSMzODI1MzUwIzIxOTI5NTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/","name":"BioXcel Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTQ2MSMzODI1MzUwIzIxOTI5NTc=","datePublished":"2020-11-13T12:03:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTQ2MSMzODI1MzUwIzIxOTI5NTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTQ2MSMzODI1MzUwIzIxOTI5NTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioxcel-therapeutics-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BioXcel Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/380655","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=380655"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/380655\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=380655"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=380655"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=380655"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}